✦ LIBER ✦

Evaluation of the new polyclonal rabbit anti-human HER2/neu antibody — Overexpression of HER2/neu in ovarian cancer is associated with shortened overall survival

✍ Scribed by R. Emig; C. Zeeb; N. Fersis; P. Ruck; H.B.G. Franz; O. Tomé; S.S. Köhler; B. Bültmann; U. Wagner; D. Wallwiener

Book ID: 117667871
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 318 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)81332-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose escalation and pharmacokinetic stud

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

✍ Tokuda, Y; Watanabe, T; Omuro, Y; Ando, M; Katsumata, N; Okumura, A; Ohta, M; Fu 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 331 KB

Decreased Survival of Human Breast Cance

Decreased Survival of Human Breast Cancer Cells Expressing HER2/neu on In vitro Incubation with an Anti-HER2/neu Antibody Fused to C5a or C5adesArg

✍ Fuenmayor, J.; Perez-Vazquez, K.; Perez-Witzke, D.; Penichet, M. L.; Montano, R. 📂 Article 📅 2010 🏛 American Association for Cancer Research 🌐 English ⚖ 367 KB

Elevation of the serum HER2/neu level is

Elevation of the serum HER2/neu level is associated with shorter progression-free survival after chemotherapy in metastatic breast cancer

✍ D. Lueftner; C. Akrivakis; P. Henschke; B. Flath; R. Geppert; K. Wernecke; K. Po 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 372 KB

Evaluation of Monoclonal Humanized Anti-

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

✍ Bookman, M. A. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 108 KB

Clinical evaluation of the bispecific an

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer

✍ H. H. van Ojik; R. Repp; Gerard Groenewegen; Thomas Valerius; Jan G. J. van de W 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 332 KB